Parabilis Medicines
Cambridge, MA, USA
Why join us? Parabilis Medicines is a highly distinctive young biopharmaceutical company whose intention is to grow over time into the ranks of major therapeutics companies. Our foundational platform of Helicon™ therapeutics are peptides capable of efficient cell entry and modulation of both protein-protein and protein-DNA interactions. Through Helicon therapeutics, Parabilis is poised to revolutionize the medical possibilities for patients by precisely drugging intracellular targets long understood to be significant drivers of disease but never before drugged due to the limitations of existing drug modalities to act within the cell. An important distinctive element of Parabilis is our lead program FOG-001, the company's first-in-class TCF-blocking β-catenin inhibitor. This compound is approximately 18 months and ~50 patients into our early development program for patients with advanced solid tumors, most importantly colorectal cancer. There are few products in the ecosystem...